Yang (Carsten) Lu, Adlai Nortye CEO

With its ex-No­var­tis can­cer drug near the fin­ish line, Ad­lai Nortye rais­es $97.5M in Nas­daq de­but

The Nas­daq is wel­com­ing an­oth­er com­pa­ny hus­tling along a late-stage drug, with Ad­lai Nortye rais­ing $97.5 mil­lion from an IPO and …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.